Published in Diabetes Obes Metab on January 16, 2014
Establishment of a general NAFLD scoring system for rodent models and comparison to human liver pathology. PLoS One (2014) 0.89
PCSK9 inhibition fails to alter hepatic LDLR, circulating cholesterol, and atherosclerosis in the absence of ApoE. J Lipid Res (2014) 0.86
Salsalate attenuates diet induced non-alcoholic steatohepatitis in mice by decreasing lipogenic and inflammatory processes. Br J Pharmacol (2015) 0.79
Comment on "Hypercholesterolemia with consumption of PFOA-laced Western diets is dependent on strain and sex of mice" by Rebholz S.L. et al. Toxicol. Rep. 2016 (3) 46-54. Toxicol Rep (2016) 0.75
Male apoE*3-Leiden.CETP mice on high-fat high-cholesterol diet exhibit a biphasic dyslipidemic response, mimicking the changes in plasma lipids observed through life in men. Physiol Rep (2017) 0.75
Early thrombolytic treatment in acute myocardial infarction: reappraisal of the golden hour. Lancet (1996) 8.50
Genetic determination of telomere size in humans: a twin study of three age groups. Am J Hum Genet (1994) 7.04
Role of ApoCs in lipoprotein metabolism: functional differences between ApoC1, ApoC2, and ApoC3. Arterioscler Thromb Vasc Biol (1999) 2.75
Apolipoprotein E4 allele in a population-based study of early-onset Alzheimer's disease. Nat Genet (1994) 2.65
Conjugation deficient E. coli K12 F- mutants with heptose-less lipopolysaccharide. Mol Gen Genet (1976) 2.22
Postprandial triglyceride response in young adult men and familial risk for coronary atherosclerosis. Ann Intern Med (1994) 2.11
Macrophage p53 deficiency leads to enhanced atherosclerosis in APOE*3-Leiden transgenic mice. Circ Res (2001) 1.91
Macrophage scavenger receptor class A: A multifunctional receptor in atherosclerosis. Arterioscler Thromb Vasc Biol (2000) 1.89
Hepatic steatosis: a mediator of the metabolic syndrome. Lessons from animal models. Arterioscler Thromb Vasc Biol (2004) 1.79
No effect of C-reactive protein on early atherosclerosis development in apolipoprotein E*3-leiden/human C-reactive protein transgenic mice. Arterioscler Thromb Vasc Biol (2005) 1.70
Association between apolipoprotein E epsilon4 and the rate of cognitive decline in community-dwelling elderly individuals with and without dementia. Arch Neurol (1998) 1.67
Integrative noetic therapies as adjuncts to percutaneous intervention during unstable coronary syndromes: Monitoring and Actualization of Noetic Training (MANTRA) feasibility pilot. Am Heart J (2001) 1.66
High-yield noninvasive human genomic DNA isolation method for genetic studies in geographically dispersed families and populations. Am J Hum Genet (1995) 1.62
Diet-induced hyperlipoproteinemia and atherosclerosis in apolipoprotein E3-Leiden transgenic mice. J Clin Invest (1994) 1.56
Apolipoprotein C-III deficiency accelerates triglyceride hydrolysis by lipoprotein lipase in wild-type and apoE knockout mice. J Lipid Res (2001) 1.43
Transgenic mice carrying the apolipoprotein E3-Leiden gene exhibit hyperlipoproteinemia. J Biol Chem (1993) 1.41
Effect of apolipoprotein E and insulin resistance on VLDL particles in combined hyperlipidemic patients. Atherosclerosis (1996) 1.40
Scavenger receptor deficiency leads to more complex atherosclerotic lesions in APOE3Leiden transgenic mice. Atherosclerosis (1999) 1.33
Exact localization of the familial dysbetalipoproteinemia associated HpaI restriction site in the promoter region of the APOC1 gene. Biochem Biophys Res Commun (1988) 1.31
Apolipoprotein e4 allele and cognitive decline in elderly men. BMJ (1994) 1.31
Protection from obesity in mice lacking the VLDL receptor. Arterioscler Thromb Vasc Biol (2001) 1.28
Diet-induced hypercholesterolemia and atherosclerosis in heterozygous apolipoprotein E-deficient mice. Atherosclerosis (1994) 1.28
In muscle-specific lipoprotein lipase-overexpressing mice, muscle triglyceride content is increased without inhibition of insulin-stimulated whole-body and muscle-specific glucose uptake. Diabetes (2001) 1.25
Hyperlipidemia and cutaneous abnormalities in transgenic mice overexpressing human apolipoprotein C1. J Clin Invest (1998) 1.23
Shifting the open-artery hypothesis downstream: the quest for optimal reperfusion. J Am Coll Cardiol (2001) 1.22
Impaired secretion of very low density lipoprotein-triglycerides by apolipoprotein E- deficient mouse hepatocytes. J Clin Invest (1997) 1.20
Quantitative assessment of aortic atherosclerosis in APOE*3 Leiden transgenic mice and its relationship to serum cholesterol exposure. Arterioscler Thromb Vasc Biol (1996) 1.20
Low density lipoprotein receptor internalizes low density and very low density lipoproteins that are bound to heparan sulfate proteoglycans via lipoprotein lipase. J Biol Chem (1993) 1.19
A rapid micromethod for apolipoprotein E phenotyping directly in serum. J Lipid Res (1987) 1.15
Mdm2, but not Mdm4, protects terminally differentiated smooth muscle cells from p53-mediated caspase-3-independent cell death. Cell Death Differ (2006) 1.15
Cartilage degradation and invasion by rheumatoid synovial fibroblasts is inhibited by gene transfer of TIMP-1 and TIMP-3. Gene Ther (2003) 1.14
Characterization of an Escherichia coli K-12 F-Con-mutant. J Bacteriol (1976) 1.13
Protection from obesity and insulin resistance in mice overexpressing human apolipoprotein C1. Diabetes (2001) 1.10
Strong decrease of high sensitivity C-reactive protein with high-dose atorvastatin in patients with type 2 diabetes mellitus. Atherosclerosis (2003) 1.07
Intracerebroventricular administration of melanotan II increases insulin sensitivity of glucose disposal in mice. Diabetologia (2005) 1.07
Genetic heterogeneity of apolipoprotein E and its influence on plasma lipid and lipoprotein levels. Hum Mutat (1994) 1.07
Apolipoprotein E genotype and association between smoking and early onset Alzheimer's disease. BMJ (1995) 1.06
Apolipoprotein E participates in the regulation of very low density lipoprotein-triglyceride secretion by the liver. J Biol Chem (1999) 1.06
Fenofibrate reduces atherogenesis in ApoE*3Leiden mice: evidence for multiple antiatherogenic effects besides lowering plasma cholesterol. Arterioscler Thromb Vasc Biol (2006) 1.05
Progression and regression of atherosclerosis in APOE3-Leiden transgenic mice: an immunohistochemical study. Atherosclerosis (1999) 1.04
Atypical xanthomatosis in apolipoprotein E-deficient mice after cholesterol feeding. Atherosclerosis (1995) 1.03
The mouse low density lipoprotein receptor gene: cDNA sequence and exon-intron structure. Biochem Biophys Res Commun (1993) 1.03
Association of the -2849 interleukin-10 promoter polymorphism with autoantibody production and joint destruction in rheumatoid arthritis. Arthritis Rheum (2003) 1.02
Domains of apolipoprotein E contributing to triglyceride and cholesterol homeostasis in vivo. Carboxyl-terminal region 203-299 promotes hepatic very low density lipoprotein-triglyceride secretion. J Biol Chem (2001) 1.01
Macrophage low-density lipoprotein receptor-related protein deficiency enhances atherosclerosis in ApoE/LDLR double knockout mice. Arterioscler Thromb Vasc Biol (2006) 1.01
Effect of human scavenger receptor class A overexpression in bone marrow-derived cells on cholesterol levels and atherosclerosis in ApoE-deficient mice. Arterioscler Thromb Vasc Biol (2000) 1.01
Stimulation of the LDL receptor activity in the human hepatoma cell line Hep G2 by high-density serum fractions. Biochim Biophys Acta (1986) 1.01
Serum apolipoprotein E level is not increased in Alzheimer's disease: the Rotterdam study. Neurosci Lett (1998) 1.01
Raman spectroscopic evaluation of the effects of diet and lipid-lowering therapy on atherosclerotic plaque development in mice. Arterioscler Thromb Vasc Biol (2001) 1.01
Heparan sulphate proteoglycans are involved in the lipoprotein lipase-mediated enhancement of the cellular binding of very low density and low density lipoproteins. Biochem Biophys Res Commun (1992) 1.01
In the absence of the low density lipoprotein receptor, human apolipoprotein C1 overexpression in transgenic mice inhibits the hepatic uptake of very low density lipoproteins via a receptor-associated protein-sensitive pathway. J Clin Invest (1996) 1.00
The dopamine receptor D2 agonist bromocriptine inhibits glucose-stimulated insulin secretion by direct activation of the alpha2-adrenergic receptors in beta cells. Biochem Pharmacol (2010) 1.00
Epitopes of apolipoprotein B-100 and B-48 in both liver and intestine. Expression and evidence for local synthesis in recessive abetalipoproteinemia. J Clin Invest (1986) 0.99
Familial dysbetalipoproteinemia associated with apolipoprotein E3-Leiden in an extended multigeneration pedigree. J Clin Invest (1991) 0.99
Apolipoprotein E genotype, atherosclerosis, and cognitive decline: the Rotterdam Study. J Neural Transm Suppl (1998) 0.99
Autoantibodies against mannose-binding lectin in systemic lupus erythematosus. Clin Exp Immunol (2003) 0.99
Sustained activation of the mammalian target of rapamycin nutrient sensing pathway is associated with hepatic insulin resistance, but not with steatosis, in mice. Diabetologia (2006) 0.98
The apolipoprotein E epsilon 2 allele is associated with an increased risk of early-onset Alzheimer's disease and a reduced survival. Ann Neurol (1995) 0.98
Transgenic mouse models to study the role of APOE in hyperlipidemia and atherosclerosis. Atherosclerosis (1998) 0.97
Hepatic steatosis and very low density lipoprotein secretion: the involvement of apolipoprotein E. J Hepatol (2001) 0.96
White adipose tissue: getting nervous. J Neuroendocrinol (2003) 0.96
Apolipoprotein E is resistant to intracellular degradation in vitro and in vivo. Evidence for retroendocytosis. J Biol Chem (2000) 0.95
LDL receptor deficiency unmasks altered VLDL triglyceride metabolism in VLDL receptor transgenic and knockout mice. J Lipid Res (2000) 0.95
Nascent very-low-density lipoprotein triacylglycerol hydrolysis by lipoprotein lipase is inhibited by apolipoprotein E in a dose-dependent manner. Biochem J (1997) 0.94
Effect of human scavenger receptor class A overexpression in bone marrow-derived cells on lipoprotein metabolism and atherosclerosis in low density lipoprotein receptor knockout mice. J Lipid Res (2000) 0.94
The B domain of coagulation factor VIII interacts with the asialoglycoprotein receptor. J Thromb Haemost (2005) 0.94
Living up to a name: the role of the VLDL receptor in lipid metabolism. Curr Opin Lipidol (2001) 0.94
Severe learning deficits in apolipoprotein E-knockout mice in a water maze task. Brain Res (1997) 0.94
Lipoprotein lipase stimulates the binding and uptake of moderately oxidized low-density lipoprotein by J774 macrophages. Biochem J (1996) 0.93
Both lipolysis and hepatic uptake of VLDL are impaired in transgenic mice coexpressing human apolipoprotein E*3Leiden and human apolipoprotein C1. Arterioscler Thromb Vasc Biol (1996) 0.93
Acyl-CoA:cholesterol acyltransferase inhibitor avasimibe reduces atherosclerosis in addition to its cholesterol-lowering effect in ApoE*3-Leiden mice. Circulation (2001) 0.93
Regulation of low density lipoprotein receptor activity in primary cultures of human hepatocytes by serum lipoproteins. Hepatology (1987) 0.92
Accelerated atherosclerosis by placement of a perivascular cuff and a cholesterol-rich diet in ApoE*3Leiden transgenic mice. Circ Res (2000) 0.92
The effect of (-)-hydroxycitrate on the activity of the low-density-lipoprotein receptor and 3-hydroxy-3-methylglutaryl-CoA reductase levels in the human hepatoma cell line Hep G2. Biochem J (1990) 0.92
Leptin deficiency per se dictates body composition and insulin action in ob/ob mice. J Neuroendocrinol (2008) 0.92
ApoE polymorphism and predisposition to coronary heart disease in youths of different European populations. The EARS Study. European Atherosclerosis Research Study. Arterioscler Thromb (1994) 0.91
The lipoprotein lipase (Asn291-->Ser) mutation is associated with elevated lipid levels in families with familial combined hyperlipidaemia. Atherosclerosis (1996) 0.91
Logistics and quality control for DNA sampling in large multicenter studies. J Thromb Haemost (2003) 0.91
Gut-brain axis: regulation of glucose metabolism. J Neuroendocrinol (2006) 0.91
The mouse apolipoprotein C1 gene: structure and expression. Genomics (1993) 0.91
Reduced levels of cholesterol, phospholipids, and fatty acids in cerebrospinal fluid of Alzheimer disease patients are not related to apolipoprotein E4. Alzheimer Dis Assoc Disord (1998) 0.91
Mutations in the low density lipoprotein receptor gene of familial hypercholesterolemic patients detected by denaturing gradient gel electrophoresis and direct sequencing. J Lipid Res (1995) 0.90
Evolutionary conservation of the mouse apolipoprotein e-c1-c2 gene cluster: structure and genetic variability in inbred mice. Genomics (1993) 0.90
ApoE polymorphism accounts for only part of the genetic variation in quantitative ApoE levels. Genet Epidemiol (2000) 0.90
Exendin-4 decreases liver inflammation and atherosclerosis development simultaneously by reducing macrophage infiltration. Br J Pharmacol (2014) 0.90
ST-Segment recovery adds to the assessment of TIMI 2 and 3 flow in predicting infarct wall motion after thrombolytic therapy. Circulation (2000) 0.89
Additional risk factors influence excess mortality in heterozygous familial hypercholesterolaemia. Atherosclerosis (2000) 0.89
Apolipoprotein E protects against neuropathology induced by a high-fat diet and maintains the integrity of the blood-brain barrier during aging. Lab Invest (2001) 0.89
Reversal of hyperlipidaemia in apolipoprotein C1 transgenic mice by adenovirus-mediated gene delivery of the low-density-lipoprotein receptor, but not by the very-low-density-lipoprotein receptor. Biochem J (1999) 0.88
Mortality risk in men is associated with a common mutation in the methylene-tetrahydrofolate reductase gene (MTHFR). Eur J Hum Genet (1999) 0.88
Dietary plant stanol esters reduce VLDL cholesterol secretion and bile saturation in apolipoprotein E*3-Leiden transgenic mice. Arterioscler Thromb Vasc Biol (2001) 0.87
Cafestol increases serum cholesterol levels in apolipoprotein E*3-Leiden transgenic mice by suppression of bile acid synthesis. Arterioscler Thromb Vasc Biol (2000) 0.87
Decrease of hemostatic cardiovascular risk factors by aggressive vs. conventional atorvastatin treatment in patients with Type 2 diabetes mellitus. J Thromb Haemost (2003) 0.87
Structure and expression of the mouse apolipoprotein C2 gene. Genomics (1993) 0.87
Apolipoprotein E3-Leiden contains a seven-amino acid insertion that is a tandem repeat of residues 121-127. J Biol Chem (1989) 0.86
The binding of human lipoprotein lipase treated VLDL by the human hepatoma cell line HepG2. Biochim Biophys Acta (1991) 0.86